Stockscreener 앱 받기
2.485
1.21%
0.015
Lipocine Inc 주식(LPCN)의 최신 뉴스
Form 4 Lipocine Inc For: 30 June By Investing.com - Investing.com Canada
Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant - Stock Titan
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Remains KeyProfit Inflection Point - dars.gov.et
Enterprise value to revenue forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to book forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Enterprise value to EBITDA forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to sales forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Lipocine Inc Actuals & Estimates (NASDAQ:LPCN) - TradingView
LPCN Forecast — Price Target — Prediction for 2027 - TradingView
Lipocine Inc (LPCN) Institutional Confidence - TradingKey
Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lipocine Inc (LPCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
LPCN News | LIPOCINE INC (NASDAQ:LPCN) - ChartMill
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
LPCN Q1 2026 Earnings: EPS Misses Estimates as No Revenue Reported; Stock Edges Higher - newsline.com
Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154 - Stock Titan
LPCN: LPCN 1154 demonstrated rapid, sustained PPD relief with a short, well-tolerated oral regimen - TradingView
LPCN Q1 2026 Earnings: Wider-Than-Anticipated Loss Reflects Continued R&D SpendingGuidance Update - newsline.com
Lipocine Inc. (LPCN) Extends Decline: Key Support Levels in Focus After 7% DropStock Analysis - newsline.com
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan - Stock Titan
Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19 - Stock Titan
Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price - Stock Titan
Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19 - Stock Titan
Lipocine Plans KOL Webinar on Oral PPD Candidate - TipRanks
Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression - TradingView
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - Nasdaq
Lipocine (LPCN) Holds Near $2.25 Support Zone as Market Waits for CatalystsIV Crush Alert - newsline.com
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues to Advance PipelineFinancial Health Score - The Legal Advocate
LPCNLipocine Inc Stock Price and Quote - Finviz
Lipocine Inc. (LPCN) Edges Higher Amid Modest Uptick: Technical Resistance in SightSector Neutral Pair - newsline.com
Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP - TradingView
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Lipocine Inc. (LPCN) Edges Higher as Biotech Stock Holds Above Key SupportDividend ETF - The Legal Advocate
Lipocine Inc. (LPCN) Shows Modest Uptick, Trading Near Key Resistance LevelTRIN Signal - The Legal Advocate
Lipocine Inc. (LPCN) Shows Resilience: Breaking Down the $2.26 RallyVolume Rate Change - thelegaladvocate.com
LPCN SEC FilingsLipocine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lipocine (LPCN) reports Q1 loss, beats revenue estimates - MSN
LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD - TradingView
LPCN: Rapid-acting oral PPD therapy shows promise in subgroups, with funding secured for next trial - TradingView
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Pres - GuruFocus
Lipocine Announces Phase 3 Data for LPCN 1154 (Oral Brexanolone) in Postpartum Depression Selected for Oral Presentation at 2026 ASCP Annual Meeting 1 - Minichart
Lipocine’s postpartum depression drug data to be presented at ASCP By Investing.com - Investing.com South Africa
Lipocine’s postpartum depression drug data to be presented at ASCP - Investing.com UK
Lipocine Showcases Phase 3 Data for Postpartum Depression - TipRanks
Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting - TradingView
Lipocine (NASDAQ: LPCN) to present LPCN 1154 Phase 3 postpartum depression data - Stock Titan
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - The Herald Journal
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase - Sahm
Lipocine to Present Innovative Oral Therapeutics Pipeline at A.G.P.’s Annual Virtual Healthcare Showcase 2026 - Minichart
Lipocine Showcases Pipeline at Virtual Healthcare Conference - TipRanks
Lipocine to Present at A.G.P. Virtual Healthcare Showcase May 20 - TradingView
1.21%
3.14%
자본화:
|
볼륨(24시간):